schliessen

Filtern

 

Bibliotheken

Pharmacokinetics of cisplatin and its monohydrated complex in humans.

The binding of the adenosine A2A receptor selective agonist 2-[4-(2-p-carboxyethyl)phenylamino] -5'-N-ethylcarboxamidoadenosine (CGS 21680) to the rat hippocampal and cerebral cortical membranes was studied and compared with that to striatal membranes. [3H] CGS 21680, in the concentration range test... Full description

Journal Title: Journal of pharmaceutical sciences August 1996, Vol.85(8), pp.824-827
Main Author: Andersson, A
Other Authors: Fagerberg, J , Lewensohn, R , Ehrsson, H
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-3549
Link: http://search.proquest.com/docview/78428456/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest78428456
title: Pharmacokinetics of cisplatin and its monohydrated complex in humans.
format: Article
creator:
  • Andersson, A
  • Fagerberg, J
  • Lewensohn, R
  • Ehrsson, H
subjects:
  • Antineoplastic Agents–Metabolism
  • Area Under Curve–Pharmacokinetics
  • Cisplatin–Therapeutic Use
  • Esophageal Neoplasms–Metabolism
  • Humans–Pharmacokinetics
  • Pharyngeal Neoplasms–Therapeutic Use
  • Water–Drug Therapy
  • Water–Drug Therapy
  • Water–Metabolism
  • Antineoplastic Agents
  • Water
  • Cisplatin
ispartof: Journal of pharmaceutical sciences, August 1996, Vol.85(8), pp.824-827
description: The binding of the adenosine A2A receptor selective agonist 2-[4-(2-p-carboxyethyl)phenylamino] -5'-N-ethylcarboxamidoadenosine (CGS 21680) to the rat hippocampal and cerebral cortical membranes was studied and compared with that to striatal membranes. [3H] CGS 21680, in the concentration range tested (0.2-200 nM), bound to a single site with a Kd of 58 nM and a Bmax of 353 fmol/mg protein in the hippocampus, and with a Kd of 58 nM and a Bmax of 264 fmol/mg protein in the cortex; in the striatum, the single high-affinity [3H] CGS 21680 binding site had a Kd of 17 nM and a Bmax of 419 fmol/mg protein. Both guanylylimidodiphosphate (100 microM) and Na+ (100 mM) reduced the affinity of [3H] CGS 21680 binding in the striatum by half and virtually abolished [3H] CGS 21680 binding in the hippocampus and cortex. The displacement curves of [3H] CGS 21680 binding with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), N6-cyclohexyladenosine (CHA), 5'-N-ethylcarboxamidoadenosine (NECA) and 2-chloroadenosine (CADO) were biphasic in the hippocampus and cortex as well as in the striatum. The predominant [3H]CGS 21680 binding site in the striatum (80%) had a pharmacological profile compatible with A2A receptors and was also present in the hippocampus and cortex, representing 10-25% of [3H]CGS 21680 binding. The predominant [3H]CGS 21680 binding site in the hippocampus and cortex had a pharmacological profile distinct from A2A receptors: the relative potency order of adenosine antagonists DPCPX, 1,3-dipropyl- 8-¿4-[(2-aminoethyl)amino]carbonylmethyl- oxyphenyl¿ xanthine (XAC), 8-(3-chlorostyryl)caffeine (CSC), and (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)- methylxanthine (KF 17,837) as displacers of [3H] CGS 21680 (5 nM) binding in the hippocampus and cerebral cortex was DPCPX > XAC >> CSC approximately KF 17,837, and the relative potency order of adenosine agonists CHA, NECA, CADO, 2-[(2-aminoethylamino)carbonylethylphenylethylamino]-5'-N- ethylcarboxamidoadenosine (APEC), and 2-phenylaminoadenosine (CV 1808) was CHA approximately NECA > or = CADO > APEC approximately CV1808 > CGS 21680. In the presence of DPCPX (20 nM), [3H] CGS 21680 (0.2-200 nM) bound to a site (A2A-like) with a Kd of 20 nM and a Bmax of 56fmol/mg protein in the hippocampus and with a Kd of 22 nM and a Bmax of 63fmol/mg protein in the cortex. In the presence of CSC (200 nM), [3H]CGS 21680(0.2-200 nM) bound to a second high-affinity site with a Kd of 97 nM and a Bmax of 255 fmol/mg protein in the hippocampus
language: eng
source:
identifier: ISSN: 0022-3549
fulltext: fulltext
issn:
  • 00223549
  • 0022-3549
url: Link


@attributes
ID1457623263
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid78428456
sourceidproquest
recordidTN_proquest78428456
sourcesystemOther
pqid78428456
galeid18982095
ingidasahp/jah/2013/00000042/00000001/art00003
display
typearticle
titlePharmacokinetics of cisplatin and its monohydrated complex in humans.
creatorAndersson, A ; Fagerberg, J ; Lewensohn, R ; Ehrsson, H
contributorAndersson, A (correspondence author) ; Andersson, A (record owner)
ispartofJournal of pharmaceutical sciences, August 1996, Vol.85(8), pp.824-827
identifierISSN: 0022-3549
subjectAntineoplastic Agents–Metabolism ; Area Under Curve–Pharmacokinetics ; Cisplatin–Therapeutic Use ; Esophageal Neoplasms–Metabolism ; Humans–Pharmacokinetics ; Pharyngeal Neoplasms–Therapeutic Use ; Water–Drug Therapy ; Water–Drug Therapy ; Water–Metabolism ; Antineoplastic Agents ; Water ; Cisplatin
languageeng
source
descriptionThe binding of the adenosine A2A receptor selective agonist 2-[4-(2-p-carboxyethyl)phenylamino] -5'-N-ethylcarboxamidoadenosine (CGS 21680) to the rat hippocampal and cerebral cortical membranes was studied and compared with that to striatal membranes. [3H] CGS 21680, in the concentration range tested (0.2-200 nM), bound to a single site with a Kd of 58 nM and a Bmax of 353 fmol/mg protein in the hippocampus, and with a Kd of 58 nM and a Bmax of 264 fmol/mg protein in the cortex; in the striatum, the single high-affinity [3H] CGS 21680 binding site had a Kd of 17 nM and a Bmax of 419 fmol/mg protein. Both guanylylimidodiphosphate (100 microM) and Na+ (100 mM) reduced the affinity of [3H] CGS 21680 binding in the striatum by half and virtually abolished [3H] CGS 21680 binding in the hippocampus and cortex. The displacement curves of [3H] CGS 21680 binding with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), N6-cyclohexyladenosine (CHA), 5'-N-ethylcarboxamidoadenosine (NECA) and 2-chloroadenosine (CADO) were biphasic in the hippocampus and cortex as well as in the striatum. The predominant [3H]CGS 21680 binding site in the striatum (80%) had a pharmacological profile compatible with A2A receptors and was also present in the hippocampus and cortex, representing 10-25% of [3H]CGS 21680 binding. The predominant [3H]CGS 21680 binding site in the hippocampus and cortex had a pharmacological profile distinct from A2A receptors: the relative potency order of adenosine antagonists DPCPX, 1,3-dipropyl- 8-¿4-[(2-aminoethyl)amino]carbonylmethyl- oxyphenyl¿ xanthine (XAC), 8-(3-chlorostyryl)caffeine (CSC), and (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)- methylxanthine (KF 17,837) as displacers of [3H] CGS 21680 (5 nM) binding in the hippocampus and cerebral cortex was DPCPX > XAC >> CSC approximately KF 17,837, and the relative potency order of adenosine agonists CHA, NECA, CADO, 2-[(2-aminoethylamino)carbonylethylphenylethylamino]-5'-N- ethylcarboxamidoadenosine (APEC), and 2-phenylaminoadenosine (CV 1808) was CHA approximately NECA > or = CADO > APEC approximately CV1808 > CGS 21680. In the presence of DPCPX (20 nM), [3H] CGS 21680 (0.2-200 nM) bound to a site (A2A-like) with a Kd of 20 nM and a Bmax of 56fmol/mg protein in the hippocampus and with a Kd of 22 nM and a Bmax of 63fmol/mg protein in the cortex. In the presence of CSC (200 nM), [3H]CGS 21680(0.2-200 nM) bound to a second high-affinity site with a Kd of 97 nM and a Bmax of 255 fmol/mg protein in the hippocampus and with a Kd of 112 nM and a Bmax of 221 fmol/mg protein in the cortex. Two pharmacologically distinct [3H]CGS 21680 binding sites were found in synaptosomal membranes of the hippocampus and cortex and in the striatum, one corresponding to A2A receptors and the other to the second high-affinity [3H]CGS 21680 binding site. In contrast, the pharmacology of [3H]CHA binding was similar in synaptosomal membranes of the three brain areas. The present results establish the existence of at least two high-affinity [3H]CGS 21680 binding sites in the CNS and demonstrate that the [3H]CGS 21680 binding site predominant in the hippocampus and cerebral cortex has different binding characteristics from the classic A2A adenosine receptor, which predominates in the striatum.
version86
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/78428456/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Andersson, A
1Fagerberg, J
2Lewensohn, R
3Ehrsson, H
titlePharmacokinetics of cisplatin and its monohydrated complex in humans.
subject
0Antineoplastic Agents–Metabolism
1Area Under Curve–Pharmacokinetics
2Cisplatin–Therapeutic Use
3Esophageal Neoplasms–Metabolism
4Humans–Pharmacokinetics
5Pharyngeal Neoplasms–Therapeutic Use
6Water–Drug Therapy
7Water–Metabolism
8Antineoplastic Agents
9Water
10Cisplatin
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Biological Science Database
6Natural Science Collection
7SciTech Premium Collection
8Health Research Premium Collection
9Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest78428456
issn
000223549
10022-3549
rsrctypearticle
creationdate1996
addtitleJournal of pharmaceutical sciences
searchscope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
scope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
lsr43
01007527false
11007944false
210000004false
310000038false
410000050false
510000120false
610000159false
710000238false
810000253false
910000260false
1010000270false
1110000271false
1210000302false
contributorAndersson, A
startdate19960801
enddate19960801
citationpf 824 pt 827 vol 85 issue 8
lsr30VSR-Enriched:[issn, description, eissn, pqid, doi, galeid, ingid]
sort
titlePharmacokinetics of cisplatin and its monohydrated complex in humans.
authorAndersson, A ; Fagerberg, J ; Lewensohn, R ; Ehrsson, H
creationdate19960801
lso0119960801
facets
frbrgroupid7178701495706221502
frbrtype5
newrecords20181218
languageeng
creationdate1996
topic
0Antineoplastic Agents–Metabolism
1Area Under Curve–Pharmacokinetics
2Cisplatin–Therapeutic Use
3Esophageal Neoplasms–Metabolism
4Humans–Pharmacokinetics
5Pharyngeal Neoplasms–Therapeutic Use
6Water–Drug Therapy
7Water–Metabolism
8Antineoplastic Agents
9Water
10Cisplatin
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Andersson, A
1Fagerberg, J
2Lewensohn, R
3Ehrsson, H
jtitleJournal of pharmaceutical sciences
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Andersson
1Fagerberg
2Lewensohn
3Ehrsson
aufirst
0A
1J
2R
3H
au
0Andersson, A
1Fagerberg, J
2Lewensohn, R
3Ehrsson, H
addauAndersson, A
atitlePharmacokinetics of cisplatin and its monohydrated complex in humans.
jtitleJournal of pharmaceutical sciences
risdate19960801
volume85
issue8
spage824
epage827
pages824-827
issn
00022-3549
100281298
formatjournal
genrearticle
ristypeJOUR
urlhttp://search.proquest.com/docview/78428456/
doi10.1016/0006-8993(96)00208-9
eissn18726240
date1996-08-01